This targeted binding may facilitate selective delivery of cytotoxic proteins, microRNAs, or other immunomodulatory cargo contained within the exosomes, thereby amplifying anti-tumor efficacy while sparing Her2-negative cells. The gene discussed is ERBB2; the disease is neoplasm.